Further studies are needed to clarify the relationship between the upregulation of CAMP expression and immune response outcomes, as well as to elucidate the pathophysiological mechanism in post-COVID-19 GBS patients. The gene discussed is CAMP; the disease is Guillain-Barre syndrome.